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Background: Hypoglycaemia is an acute complication of diabetes mellitus which poses a serious threat. This study
aims to describe the annual rate of people suffering episodes of severe hypoglycaemia and to estimate the
healthcare costs for individuals who have suffered such events.
Methods: A descriptive study involving all patients with type 2 diabetes (T2DM) from the Basque Country (period:
1/09/2010 to 31/08/2011) aged ≥35 years (N = 134,413). The rate of hypoglycaemic episodes treated in hospitals
(Accident and Emergency and in-patient services) was calculated using an algorithm based on diagnostics and
laboratory tests. The variables recorded included demographic, comorbidity (diagnoses categorised using the
Adjusted Clinical Groups case-mix system) and socioeconomic variables (deprivation index of the area of residence).
The annual healthcare cost for people with T2DM who suffered those episodes was compared with those who did
not by regression analysis.
Results: The incidence of hypoglycaemia in the Basque Country was 0.56 %. This percentage was higher among
women and people with a lower socioeconomic status. These episodes were associated with age and high values
of glycosylated haemoglobin (HbA1c) > 7 %. Adjusting for the other variables, on average, people who suffered
hypoglycaemia accounted for an additional €2509 in annual healthcare costs.
Conclusions: Hypoglycaemia has high morbi-mortality and a major economic impact. As such, health services must
monitor its appearance and promote specific actions, especially in the higher risk sub-populations.
Keywords: Hypoglycaemia, Type 2 diabetes mellitus, Healthcare costs, Glycosylated haemoglobin, Socioeconomic
levelBackground
Diabetes mellitus (DM) has become one of the most im-
portant challenges faced by healthcare systems due to its
high worldwide prevalence and the high economic burden
resulting from it. By 2035, it is estimated that around 592
million people will suffer from diabetes, 210 million more
than in 2013. In addition, resource use by diabetes pa-
tients represented 10.8 % of total world healthcare costs
in 2013, ranging between 5 % and 18 % in numerous
countries [1].* Correspondence: edurne.almo@gmail.com
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unless otherwise stated.Although the majority of research into the complica-
tions of DM is aimed at studying the impact of chronic
complications on the quality of life of diabetes sufferers
and the resulting healthcare costs, hypoglycaemic epi-
sodes are a common acute complication into this group.
It is widely accepted that hypoglycaemia is an import-
ant problem as regards caring for DM patients receiving
insulin treatment [2]. However, its importance amongst
patients receiving oral antidiabetics may not be as well
recognised and the estimated burden resulting from hypo-
glycaemic episodes in diabetes mellitus type 2 (T2DM)
may therefore be underestimated.
Hypoglycaemic episodes may result in severe morbidity,
causing vascular events such as stroke, acute myocardial
infarction, acute heart failure and ventricular arrhythmiasCentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Alonso-Morán et al. BMC Health Services Research  (2015) 15:207 Page 2 of 7[3, 4]. Neuroglycopaenic symptoms, such as confusion, diz-
ziness, weakness, reduced consciousness, unstable walking,
lack of coordination and seizures are particularly serious in
the elderly population due to the higher risk of fall-related
bone fractures and injuries, together with the presence of
other comorbidities, such as osteoporosis. Moreover, eld-
erly patients are at higher risk of the hypoglycaemic epi-
sodes passing unnoticed by the patients themselves or
even by the healthcare professionals that care for them as
they can easily be confused with other diseases, such as
transient ischaemic attacks or vasovagal episodes.
In any case, hypoglycaemia prevention requires differ-
ent strategies, including regular education of the patient,
as it has been shown that patient understanding of DM
and its treatment decreases with time [5].
As regards frequency in the population, various studies
have reported hypoglycaemia rates of between 0.02 and
0.35 episodes per type two diabetes patient per year [6].
However, the methodological differences between these
studies make comparison of their results difficult. The
main discrepancies result from the type of episodes ob-
served (inclusion of episodes resolved by the patients
themselves or only those requiring medical care or hospi-
talisation), choice of the population (patients with DM
type 1 or 2, or both) or the definition of hypoglycaemia
used (blood glucose levels established to consider an event
as hypoglycaemic).
As regards the use of healthcare resources to treat
hypoglycaemia in T2DM, the results vary according to
studies undertaken in various countries. Estimation of
these costs is affected by factors such as the incidence of
hypoglycaemia, patient characteristics, an awareness of,
and attitude towards, hypoglycaemic episodes by health-
care professionals and patients, variability in the quality of
the care provided to these patients and the organisation of
the healthcare systems [2]. A review of studies conducted
in Spain estimated the cost of a single hypoglycaemic epi-
sode to be between €3000 and €3500 [7].
Very little has been published regarding the relation-
ship between hypoglycaemic events and socioeconomic
status. Leese et al. [8] observed an association between
severe hypoglycaemia and increased socioeconomic
deprivation. This was observed in patients with type 1
and 2 diabetes but was more strongly associated with
type 1 diabetes.
In order to increase our understanding of this topic, this
study, the aim of which was to determine the rate of pa-
tients who suffer severe hypoglycaemic episodes in the
whole Basque Country population with T2DM, in other
words those who require medical care in Accident and
Emergency (A&E) departments or are admitted to hos-
pital, according to their sociodemographic characteristics,
and to estimate the annual healthcare costs for such pa-
tients, was designed.Methods
The study protocol was approved by the Ethical Com-
mittee of Clinical Research of Euskadi (PI2014074).
This is a descriptive study including all T2DM patients
with public health insurance in the Basque Country in the
period between 1 September 2010 and 31 August 2011.
Osakidetza (Basque Public Health Service) has an elec-
tronic health record and other computerised sources in
which information concerning all contact between its in-
habitants and the public health service is recorded. In this
system, diagnoses are coded according to the International
Classification of Diseases (ICD-9-CM) [9], whereas the
coding system used for medicinal products is the Anatom-
ical, Therapeutic, Chemical classification system [10].
For this study, information concerning demographic
and clinical variables was obtained from the PREST
stratification database. This database combines informa-
tion from various sources (primary and specialised care,
A&E and hospital admittance registries) to obtain diag-
noses, prescriptions and procedures. With this informa-
tion, all citizens registered with Osakidetza are classified
every year using the Adjusted Clinical Group (ACG)
case-mix system [11]. A more detailed description of the
database can be found in previous publications [12].
The study population was considered to be all T2DM
patients residing in the Basque Country. To identify this
population, all patients who, according to the PREST
database, had received a diagnosis corresponding to
T2DM or unspecified DM (including their complica-
tions) at any point in their life or who had been pre-
scribed antidiabetic medication, irrespective of whether
they had made use of care services during the observa-
tion period, were included. Those patients who had a
diagnosis relating to type 1 DM at any contact or for
whom all diagnoses corresponded to unspecified DM,
but the only medication prescribed was insulin, were ex-
cluded from this group. As T2DM is rare in young
people, an age limit of 34 years was established and only
people above this threshold were analysed. As a result, a
total of 134,413 people were considered to be T2DM
patients.
Aggregated Diagnosis Groups (ADGs) were used to de-
tect the presence of diseases other than diabetes in our
study population. ADGs are a component of the ACG sys-
tem and comprise 32 diagnostic categories, which are
groups with similar severity, expected duration of the dis-
ease and treatment needs.
In addition, the glycosylated haemoglobin (HbA1c)
values for the study patients were collected. In the case
of patients with multiple determinations in the study
period, only the last value recorded was considered.
The deprivation index from the census tract of resi-
dence was used as a socioeconomic variable [13]. This
index is usually categorised into quintiles, although for
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ies, with category one corresponding to residents in the
least deprived areas and category 3 those in the most de-
prived regions.
Health care provision were calculated by cost-weighted
health care utilisation. We consider the cost of the follow-
ing services: prescribing, primary care (including visits to
physician and nurse, laboratory and radiology), specialised
outpatient care (doctor visits, rehabilitation, dialysis, radio-
therapy and chemotherapy services), A&E attendances
and inpatients stays.
In the case of prescribing, the cost was computed dir-
ectly from primary care prescriptions recorded in the
electronic health records. For the other cases (visits to
A&E, rehabilitation sessions, outpatient specialty care and
primary care doctors and nurses; lab tests and X-rays re-
quested in primary care; some procedures such as dialysis,
radiation therapy or chemotherapy performed in day hos-
pitals) the number of services used by each patient was
multiplied by their standard cost. The costs of hospital
stays and major outpatient surgical procedures were cal-
culated according to the weights of their corresponding
Diagnosis Related Groups (DRGs) [14].
Some services for which no information was available,
namely admission to psychiatric hospitals, hospital-at-
home and day hospital services (except the above-
mentioned procedures), medical transport, prostheses
and other equipment delivered to patients at home, were
excluded from the cost estimate.
For study of severe hypoglycaemic episodes, we con-
sidered those which required hospital-based care (either
resolved by A&E services or required hospitalisation).
The population was classified into two groups: persons
with no hypoglycaemic episode and those who presented
one or more.
As the hypoglycaemic episodes recorded upon discharge
from hospital are often incorrectly coded, a modification
of the algorithm proposed by Ginde et al. was used [15].
These authors considered hypoglycaemic episodes to be:
1. Those episodes assigned the corresponding ICD-9-CM
codes (251.00; 251.02; 251.10; 251.12; 251.20; 251.22).
2. Those related to intoxication with antidiabetic drugs
(code 962.3).
3. Those in which the diagnosis was coded as 250.80
or 250.82 (diabetes with other specified complaints),
excluding those which also presented one of the
following diseases as co-diagnosis: cellulitis, lower
limb ulcers, osteomyelitis, Oppenheim-Urban
syndrome, diabetic lipidosis or secondary diabetic
glycogenosis.
Although the positive predictive value (PPV) for the
episodes indicated by this third method in the study byGinde et al. exceeded 79 % of correctly identified hypo-
glycaemic episodes, in our population the PPV did not
reach 40 %. Consequently, in this latter case we decided
to add an additional criterion, namely a laboratory ana-
lysis in which a blood glucose level of <60 mg/dL was
recorded. Although this algorithm (Fig. 1) did not allow
us to include hypoglycaemic episodes diagnosed using a
reagent strip, it was found to be a specific method for
detecting these episodes.
The mean was calculated for all continual variables
and the frequency for discrete variables, stratifying by
sex, age group and deprivation index. A logistic regres-
sion analysis was performed to study the effect of the in-
dependent variables (sex, age group, deprivation index,
HbA1c and ADG) on the probability of presenting a hypo-
glycaemic episode, and a linear regression analysis was
performed to analyse the differences in annual healthcare
costs per person. Values with p <0.05 were considered to
be significant.
Statistical calculations were performed using Stata, Data
Analysis and Statistical Software, Release 12 (StataCorp,
LP, College Station, TX, USA).
Results
Of the total population of 1,473,943 persons aged ≥35
years, 134,413 presented T2DM, which corresponds to a
prevalence of 9.12 %. A total of 847 hypoglycaemic epi-
sodes were recorded in this group, therefore the average
episodes/person/year was 0.63 %.
The total number of person with T2DM attended due
to one or more hypoglycaemic episodes after one year
was 747, which represents a percentage of 0.56 %. This
value was higher in females (0.58 % vs. 0.53 % in males),
in those subjects with a lower socioeconomic level (0.62 %
for inhabitants of the most deprived regions) and in those
belonging to the younger and older age groups. These
values are summarised in Table 1.
However, the multivariate analysis showed no statistically
significant differences between sexes or socioeconomic
levels. Subjects with an HbA1c level higher than 7 % and,
in particular, younger subjects (aged 35–39 years) had a
higher probability of presenting hypoglycaemia. The results
of the logistic regression analysis are shown in Table 2.
As regards costs, it was found that patients who pre-
sented hypoglycaemic episodes generated higher overall
costs than those who did not suffer any such episode,
with the overall difference being €7605 in males and
€7280 in females (see Table 3). Thus, the primary and
specialised outpatient care and prescription costs were
twice as high in patients of both sexes with hypoglycaemic
episodes, whereas Accident and Emergency and hospital-
isation costs were five times as high.
A linear regression analysis was performed, adjusting
the cost of the healthcare provided to T2DM patients
Table 1 Stratification of patients who suffered from hypoglycaemic episodes in 2011 by age and deprivation index
N people
with T2DM
N (%) people with
hypoglycaemic episodes




N (%) females with
hypoglycaemic episodes
Distribution 134,413 747 (0.56) 72,537 386 (0.53) 61,876 361 (0.58)
Age range
35-39 1,136 11 (0.97) 661 10 (1.51) 475 1 (0.21)
40-44 2,088 8 (0.38) 1,329 6 (0.45) 759 2 (0.26)
45-49 4,141 16 (0.39) 2,804 12 (0.43) 1,337 4 (0.30)
50-54 7,504 21 (0.28) 5,094 15 (0.29) 2,410 6 (0.25)
55-59 11,310 18 (0.16) 7,442 16 (0.21) 3,868 2 (0.05)
60-64 16,119 44 (0.27) 10,191 29 (0.28) 5,928 15 (0.25)
65-69 19,205 56 (0.29) 11,366 31 (0.27) 7,839 25 (0.32)
70-74 17,402 74 (0.43) 9,588 43 (0.45) 7,814 31 (0.40)
75-79 21,686 153 (0.71) 10,805 81 (0.75) 10,881 72 (0.66)
80-84 18,054 172 (0.95) 8,055 81 (1.01) 9,999 91 (0.91)
85+ 15,768 174 (1.10) 5,202 62 (1.19) 10,566 112 (1.06)
Deprivation index
1 20,917 113 (0.53) 11,926 61 (0.51) 8,991 52 (0.57)
2 53,801 266 (0.50) 29,659 145 (0.49) 24,142 121 (0.50)
3 59,695 368 (0.62) 30,952 180 (0.58) 28,743 188 (0.65)
N represents the sample size. Deprivation index 1 represents the residents in less deprived regions and 3 represents the residents in more deprived regions
Fig. 1 Method for the inclusion an episode of hypoglycaemia
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Table 2 Odds ratio for the logistic regression model, with
suffering a hypoglycaemic episode as dependent variable
People who have suffered at least one hypoglycaemic episode
Characteristics Odds
ratio
P value [95 % Conf. interval]
Gender
Males (reference) 1
Females 1.140 0.194 0.935 1.390
Age ranges
35-39 (reference) 1
40-44 0.288 0.036 0.090 0.923
45-49 0.248 0.006 0.092 0.666
50-54 0.186 <0.001 0.074 0.466
55-59 0.123 <0.001 0.050 0.307
60-64 0.162 <0.001 0.070 0.376
65-69 0.153 <0.001 0.066 0.350
70-74 0.203 <0.001 0.090 0.458
75-79 0.274 0.001 0.124 0.607
80-84 0.336 0.007 0.151 0.745
85+ 0.334 0.008 0.149 0.751
HbA1c
HbA1c ≤7 % (reference) 1
HbA1c >7 % and HbA1c ≤ 8 % 1.651 <0.001 1.331 2.048
HbA1c >8 % and HbA1c ≤ 9 % 1.537 0.005 1.140 2.074
HbA1c >9 % 2.216 <0.001 1.653 2.972
Deprivation index
1 (reference) 1
2 0.887 0.408 0.668 1.178
3 1.028 0.846 0.781 1.351
The ADGs are not provided in this table. Please contact the authors for further
information
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tion index), comorbidity (ADGs), HbA1c levels and
hypoglycaemic episodes (Table 4). This study showed
that, on average, patients who presented a hypogly-
caemic episode accounted for €2509 more of the overall
costs (p <0.001). The average total cost was lower for







Males No 588 609
Yes 1033 1248
Total 590 611
Females No 660 563
Yes 1142 1489
Total 662 567differences based on glycaemic control level also reached
statistical significance, with lower costs being observed
for patients with HbA1c levels <7 %, intermediate costs
for those with a level between 7 % and 8 %, and the
highest costs being found for patients with HbA1c levels
>8 %.
Discussion
Although methodological differences between studies
make a comparison difficult, our findings are consistent
with the literature as the percentage of people who suf-
fered a hypoglycaemic episode (0.56 %) is in the range
described by other authors [16–18]. Similarly, the results
obtained as regards age ranges are also in accordance
with those reported by other authors, with a higher pro-
portion of episodes being observed in the younger age
groups [19, 20].
Leese et al. [8] have reported that socioeconomic level
is associated with the onset of a hypoglycaemic episode.
Although it is true that the proportion of people who
suffer at least one episode is higher in more deprived re-
gions, the logistic regression analysis performed as part
of our study did not find a statistically significant rela-
tionship between this factor and suffering at least one
such episode or not.
As we have seen previously, there is a marked differ-
ence in the estimated direct cost per severe hypogly-
caemic episode treated in hospital. Some authors have
reported this quantity to be around €1370 in Spain [21],
whereas others have reported values in the range €3000-
3500 [7]. However, a comparison is impossible as the
costs in our study are calculated on the basis of the total
annual consumption of resources needed by a person
who has suffered a hypoglycaemic episode rather than
the cost of each hypoglycaemic episode.
In the Basque Country, the average difference in an-
nual costs between people who presented one or more
hypoglycaemic episode and those who did not was
€7605 for males and €7280 for females. It should be
noted, however, that only part of this cost is attributable
to the event itself, with the remainder arising due to
other characteristics of the patient, especially the co-








74 1442 760 3472
426 6972 1397 11077
76 1467 762 3507
80 1167 838 3307
432 5979 1545 10587
82 1192 842 3345
Table 4 Linear regression analysis with total cost as dependent
variable
Total cost
Characteristics Coefficients P value [95 % Conf. interval]
Gender
Males (reference) 1
Females −129.3 <0.001 −183.6 −75.1
Age ranges
35-39 (reference) 1
40-44 25.8 0.893 −351.3 402.9
45-49 32.8 0.852 −311.5 377.1
50-54 79.3 0.636 −249.3 408.0
55-59 182.4 0.268 −140.1 504.9
60-64 340.9 0.036 22.1 659.6
65-69 363.4 0.025 46.0 680.9
70-74 412.0 0.011 93.7 730.4
75-79 481.5 0.003 164.0 799.0
80-84 422.6 0.01 103.2 742.0




Yes 2508.7 <0.001 2146.0 2871.3
Deprivation index
1 (reference) 1
2 59.6 0.135 −18.6 137.9
3 86.8 0.028 9.6 164.0
HbA1c
HbA1c ≤7 % (reference) 1
HbA1c >7 % and
HbA1c ≤ 8 %
251.5 <0.001 188.0 314.9
HbA1c >8 % and
HbA1c ≤ 9 %
561.8 <0.001 467.1 656.6
HbA1c >9 % 447.5 <0.001 340.9 554.0
The ADGs are not provided in this table. Please contact the authors for further
information
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ence attributable to the presence of hypoglycaemic epi-
sodes decreased to €2509. The use of a sophisticated
system for adjusting for comorbidity, namely the ACGs
from Johns Hopkins University, the validity of which has
been confirmed in several countries [22, 23], is one of
the strengths of our study.
Another strength is the fact that, as the study is based
on the entire T2DM population aged ≥35 years with
public health insurance (in other words essentially the
entire Basque Country population), selection biases are
avoided. Moreover, a database containing informationfrom primary care, in- and out-patient hospital care and
pharmaceutical prescriptions is used for the inclusion
criteria for T2DM patients. This is highly relevant as it
has been reported that the use of a single source may re-
sult in inaccurate calculations [24, 25], whereas the com-
bined use of various sources contributes to a better
description of health problems [26].
One drawback of our study is that administrative data-
bases only contain information regarding the problems
for which people seek medical care. Moreover, it has
proved difficult to identify hypoglycaemic episodes in
our healthcare information systems as a marked under-
reporting is commonly observed in medical notes and
administrative databases. In addition, although laboratory
results have also been used, diagnosis of a hypoglycaemic
episode is often established using a reagent strip, for
which no records are kept. Finally, some hypoglycaemic
episodes are coded as “other complications” upon dis-
charge from hospital. In light of the above, we have used a
complex method which has allowed us to overcome some
of these limitations.Conclusions
Hypoglycaemic episodes provoke various problems in
clinical practice. Thus, symptoms (and the threshold for
presenting them) vary and are often confused with other
diseases or go unnoticed. In addition, the glucose levels
accepted as pathological are not unique (various differ-
ent standards have been proposed by various scientific
societies [27]) and can often not be checked by the pa-
tient when suffering the episode. Their frequency is high,
especially as type 2 diabetes progresses with time, and
their onset cannot always be predicted. Moreover, com-
pensation can often be inadequate or excessive.
As such, education, self-control and adequate treat-
ment adherence are key objectives for managing this
condition. Patients diagnosed with T2DM who have
commenced pharmacological treatment must receive
specific training in how to recognise and treat the first
symptoms of hypoglycaemia, thereby reducing the pos-
sible complications arising from the episode. Moreover,
the creation of a suitable database for measuring and
monitoring these episodes would be advantageous as it
could then be used to target interventions at specific
sub-groups and to follow-up patients at high risk of
hypoglycaemia due to their characteristics or previous
hypoglycaemic episodes.Abbreviations
ACG: Adjusted clinical group; ADG: Aggregated diagnosis group;
A&E: Accident and emergency; DM: Diabetes mellitus; HbA1c: Glycosylated
haemoglobin; ICD-9-CM: International classification of diseases; PPV: Positive
predictive value; PREST: Basque country stratification program; T2DM: Type 2
diabetes mellitus.
Alonso-Morán et al. BMC Health Services Research  (2015) 15:207 Page 7 of 7Competing interests
This study has been funded by Esteve pharmaceutical company. The authors
have no conflicts of interest to declare.
Authors’ contributions
EAM, JFO and RNS contributed equally. All authors read and approved the
final manuscript.
Acknowledgements
The authors would like to thank the team from the MEDEA project in the
Basque Country for calculating the deprivation index and providing the data
for this index, especially Montse Calvo, for geocoding the data. We are also
grateful to the pharmaceutical company Esteve for funding and support in
order to improve our understanding of the impact of hypoglycaemic
episodes.
Permissions
Permission to access and utilize the database was obtained from Basque
Foundation for Health Innovation and Research.
Author details
1O+berri, Basque Institute for Healthcare Innovation, Torre del BEC (Bilbao
Exhibition Centre), Ronda de Azkue 1, 48902 Barakaldo, Spain. 2Osakidetza,
Basque Health Service, Centro de Salud de Astrabudua, Mezo 35, 48950
Erandio, Spain. 3Deusto Business School, University of Deusto, Hermanos
Aguirre 2, 48014 Bilbao, Spain.
Received: 16 June 2014 Accepted: 18 May 2015
References
1. International Diabetes Federation. IDF diabetes Atlas, sixth edition 2013
[http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf] [cited 2014
Feb 17].
2. Amiel SA, Dixon T, Mann R, Jameson K. Review article: hypoglycaemia in
type 2 diabetes. Diabet Med. 2008;25:245–54.
3. Landstedt-Hallin L, Adamson U, Lins P. Oral glibenclamide suppresses
glucagon secretion during insulin-induced hypoglycemia in patients with
type 2 diabetes*. J Clin Endocrinol Metab Copyr. 1999;84:3140–5.
4. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of
hypoglycemia and cardiac ischemia: a study based on continuous
monitoring. Diabetes Care. 2003;26(5):1485–9.
5. Lawrence PA, Cheely J. Deterioration of diabetic patients’ knowledge and
management skills as determined during outpatient visits. Diabetes Care.
1980;3(2):214–8.
6. Zammit NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology,
frequency, and effects of different treatment modalities. Diabetes Care.
2005;28(12):2948–61.
7. Brito-Sanfiel M, Diago-Cabezudo J, Calderon A. Economic impact of
hypoglycemia on healthcare in Spain. Expert Rev Pharmacoeconomics
Outcomes Res. 2010;10(6):649–60.
8. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, et al.
Frequency of severe hypoglycemia requiring emergency treatment in type
1 and type 2 diabetes: a population-based study of health service resource
use. Diabetes Care. 2003;26(4):1176–80.
9. Spanish Institute of Health Information. Spanish version (eCIE9MC) of
Electronic International Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) (8a Ed., Version 1.1.0) 2012 [http://
eciemaps.mspsi.es/ecieMaps/browser/index_9_mc.html].
10. Methodology TWCC for DS. International language for drug utilization
research ATC/DDD 2013 [http://www.whocc.no/atc_ddd_index/]
11. Health JHBS of P. The Johns Hopkins ACG Case-Mix System Technical
Reference Guide Manual Version 9.0. Baltimore 2009 [http://acg.jhsph.org/
public-docs/ACGv9.0TechRefGuide.pdf]
12. Orueta J, Mateos Del Pino M, Barrio Beraza I, Nuño Solinis R, Cuadrado
Zubizarreta M, Sola Sarabia C. Estratificación de la población en el País
Vasco: resultados en el primer año de implantación. Aten Primaria.
2013;45(1):54–60.
13. Domínguez-Berjón M, Borrell C, Cano-Serral G, Esnaola S, Nolasco A, Pasarín
M, et al. Construcción de un índice de privación a partir de datos censalesen grandes ciudades españolas (Proyecto MEDEA). Gac Sanit.
2008;22(3):179–87.
14. Ministerio de Sanidad Servicios Sociales e Igualdad. Registro de Altas de los
Hospitales Generales del Sistema Nacional de Salud (CMBD) [http://www.
msssi.gob.es/estadEstudios/estadisticas/cmbd.htm]
15. Ginde AA, Blanc PG, Lieberman RM, Camargo CA. Validation of ICD-9-CM
coding algorithm for improved identification of hypoglycemia visits. BMC
Endocr Disord. 2008;8:4.
16. MacLeod KM, Hepburn DA, Frier BM. Frequency and morbidity of severe
hypoglycaemia in insulin-treated diabetic patients. Diabet Med.
1993;10(3):238–45.
17. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, et al.
Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated
Type 2 diabetes: a population-based study. Diabet Med.22(6):749–55.
18. Wright AD, Cull CA, Macleod MK, Holman RR. Hypoglycemia in Type 2
diabetic patients randomized to and maintained on monotherapy with diet,
sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J
Diabetes Complications. 2006;20(6):395-401.
19. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM.
Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med.
2001;161:1653–9.
20. Quilliam BJ, Simeone JC, Ozbay AB, Stephen JK. The incidence and costs of
hypoglycemia in type 2 diabetes. Am J Manag Care. 2011;17(10):673–80.
21. Hammer M, Lammert M, Monereo Mejías S, Kern W, Frier BM. Costs of
managing severe hypoglycaemia in three European countries. J Med Econ.
2009;12(4):281–90.
22. Orueta JFM, Lopez-De-Munain JMM, Baez KM, Aiarzaguena JMMP[S],
Aranguren JIM[P], Pedrero EM[S]. Application of the ambulatory care groups
in the primary care of a European national health care system: does it work?
Med Care. 1999;37(3):238–48.
23. Lee W-C, Huang T-P. Explanatory ability of the ACG system regarding the
utilization and expenditure of the national health insurance population in
Taiwan–a 5-year analysis. J Chin Med Assoc. 2008;71(4):191–9.
24. Aubé-Maurice J, Rochette L, Blais C. Divergent associations between
incident hypertension and deprivation based on different sources of case
identification. Chronic Dis Inj Can. 2012;32(3):121–30.
25. Van den Bussche H, Schäfer I, Wiese B, Dahlhaus A, Fuchs A, Gensichen J,
et al. A comparative study demonstrated that prevalence figures on
multimorbidity require cautious interpretation when drawn from a single
database. J Clin Epidemiol. 2013;66(2):209–17.
26. Orueta JF, Nuño-Solinis R, Mateos M, Vergara I, Grandes G, Esnaola S.
Monitoring the prevalence of chronic conditions: which data should we use?
BMC Health Serv Res. 2012;12(1):365.
27. Martín Vaquero P, Barquiel Alcalá B, Puma Duque MA, Liboa Catlán A.
Hipoglucemias leves y graves en la diabetes mellitus tipo 1 y 2. Av Diabetol.
2009;25:269–79.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
